Healthcare / Drug Manufacturers - GeneralNYSE
$213.00
-4.72 (-2.17%)
FCF base 3Y
n/d
n/d CAGR · yield n/d
FCF base 5Y
n/d
n/d base · n/d expected
Precio de entrada
n/d
MOS 22% · confianza 25%
FCF escenarios
weak_data · normalized FCF $17.8B · quality 84.3/100
Ranking barato/determinista: CAGR esperado 5Y + downside bear + calidad del modelo + balance + capital allocation + data gate. No entra en buy-candidate si la data es débil o el CAGR 5Y no compensa.
SA Score
32/100
D
Piotroski
6/9
balance/quality
Valuation
50/100
+0.0% upside
5Y CAGR
+0.0%
50/100
Data QA
20/100
SEC 0%
Sin guardar todavía.
Market Cap
$376.3B
P/E
103.9x
↑EV/EBITDA
25.0x
↑ROE
-129.2%
↓Gross Margin
70.2%
↑Debt/Equity
-20.64
↓TradingView lightweight chart
Absolute Values (Left Axis)
Ratios / Percentages (Right Axis)
Financial statement dashboard
2011–2025 · 14 años de histórico normalizado
Revenue CAGR
+9.4%
FCF CAGR
—
FCF margin
29.1%
FCF / Net income
4.22x
Latest source
Provider fallback
Margin decomposition
Último año: revenue $61.16B · net income $4.23B · FCF $17.82B
Gross margin
Operating margin
Net margin
FCF margin
| Metric | TTM | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Income Statement | ||||||||||||||||
| Revenue | $61.16B | $61.16B | $56.33B | $54.32B | $58.05B | $56.20B | $45.80B | $33.27B | $32.75B | $28.22B | $25.64B | $22.86B | $19.96B | $18.79B | $18.38B | $17.44B |
| Net Income | $4.23B | $4.23B | $4.28B | $4.86B | $11.84B | $11.54B | $4.62B | $7.88B | $5.69B | $5.31B | $5.95B | $5.14B | $1.77B | $4.13B | $5.28B | $3.43B |
| EBITDA | $17.63B | $17.63B | $14.91B | $17.17B | $24.17B | — | — | — | — | — | — | — | — | — | — | — |
| EPS | 2.37 | 2.37 | 2.39 | 2.72 | 6.63 | 6.45 | 2.72 | 5.28 | 3.66 | 3.30 | 3.63 | 3.13 | 1.10 | 2.56 | 3.35 | 2.18 |
| Gross Margin | 70.2% | 70.2% | 70.0% | 62.4% | 70.0% | — | — | — | — | — | — | — | — | — | — | — |
| Operating Margin | 32.8% | 32.8% | 21.1% | 24.9% | 32.4% | 31.9% | 24.8% | 39.0% | 19.5% | 33.8% | 36.4% | 33.0% | 17.1% | 30.1% | 31.6% | 20.8% |
| Net Margin | 6.9% | 6.9% | 7.6% | 9.0% | 20.4% | 20.5% | 10.1% | 23.7% | 17.4% | 18.8% | 23.2% | 22.5% | 8.9% | 22.0% | 28.7% | 19.7% |
| Balance Sheet | ||||||||||||||||
| Debt/Equity | -20.64 | -20.64 | 20.19 | 5.73 | 3.67 | 4.93 | 6.50 | -8.23 | — | — | — | — | — | — | — | — |
| Current Ratio | 0.80 | 0.80 | — | — | — | — | — | — | — | — | — | — | — | — | — | — |
| Cash Flow | ||||||||||||||||
| Free Cash Flow | $17.82B | $17.82B | $17.83B | $22.06B | $24.25B | $21.99B | $16.79B | $12.77B | $12.79B | $9.43B | — | — | — | — | — | — |
| Returns | ||||||||||||||||
| ROE | -129.2% | -129.2% | 128.7% | 46.9% | 68.6% | 74.9% | 35.3% | -96.5% | -67.3% | 104.2% | 128.4% | 130.4% | 101.8% | 91.9% | -1507.1% | — |
| Valuation | ||||||||||||||||
| P/E | 103.89 | 103.89 | 75.36 | 59.35 | 24.38 | — | — | — | — | — | — | — | — | — | — | — |
| EV/EBITDA | 24.95 | 24.95 | 25.55 | 19.38 | 14.13 | — | — | — | — | — | — | — | — | — | — | — |
| P/B | — | — | 96.04 | 27.63 | 16.66 | — | — | — | — | — | — | — | — | — | — | — |
| Growth & Yield | ||||||||||||||||
| Revenue Growth | 8.6% | 8.6% | 3.7% | -6.4% | — | 22.7% | 37.7% | 1.6% | 16.1% | 10.1% | 12.2% | 14.5% | 6.2% | 2.2% | 5.4% | — |
| EPS Growth | -0.8% | -0.8% | -12.1% | -59.0% | — | 137.1% | -48.5% | 44.3% | 10.9% | -9.1% | 16.0% | 184.5% | -57.0% | -23.6% | 53.7% | — |
| Dividend Yield | 3.2% | 3.2% | — | — | — | — | — | — | — | — | — | — | — | — | — | — |
Revenue, Net Income & Free Cash Flow ($B)
Margins (%)
Returns (%)
Leverage & Liquidity
3Y implied EPS CAGR
99.8%
EPS terminal req.
$18.90
Spread vs growth
-100.6%
5Y implied EPS CAGR
57.4%
EPS terminal req.
$22.87
Spread vs growth
-58.2%
10Y implied EPS CAGR
31.6%
EPS terminal req.
$36.83
Spread vs growth
-32.4%
Qué te dice: cuánto EPS CAGR está descontando el precio si sales al múltiplo terminal indicado. Si el growth observado queda por debajo, el mercado está pidiendo una ejecución muy fina.
Total return
+17.6%
Start / end P/E
77.9x → 89.9x
EPS bridge
2.39 → 2.37
Residual
-0.1%
Simple additive decomposition: total return = EPS growth contribution + P/E multiple contribution + dividend contribution + explicit residual. The residual captures cross-terms, buybacks/share-count effects, FX, special dividends, data noise and methodology mismatch so the bridge always reconciles.